Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCOV1
- Development stage
- Unknown
- Lead developer
- Scancell Holdings
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
SCOV1 is a DNA-based vaccine candidate developed by Scancell Holdings for the prevention of COVID-19. Developed using Scancell's ImmunoBody platform, the vaccine is designed to induce high-avidity T-cell responses and neutralizing antibodies by targeting both the SARS-CoV-2 spike (S) protein and the nucleocapsid (N) protein. The inclusion of the N protein, which is more conserved across variants than the S protein, aims to provide broader and more durable protection against emerging SARS-CoV-2 strains. SCOV1 was evaluated in the Phase 1 COVIDITY clinical trial in South Africa, where it was administered using PharmaJet's needle-free Tropis and Stratis delivery systems to optimize DNA uptake and immunogenicity.
- Other names
- Scancell COVID-19 DNA vaccine
02
Targets
N (Nucleocapsid protein)SARS-CoV-2 spike
Beyond the preview
Go deeper on SCOV1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCOV1.